CD51 antibody

Catalog No. ABIN135791

The Mouse Monoclonal anti-CD51 antibody has been validated for IHC and FACS. It is suitable to detect CD51 in samples from Human.

Quick Overview for CD51 antibody (ABIN135791)

Target: CD51 (ITGAV) (Integrin alpha V (ITGAV))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD51 antibody is un-conjugated

Application: Immunohistochemistry (IHC), Flow Cytometry (FACS)

Clone: 13C2

Product Details anti-CD51 Antibody

Specificity: Human/African Green Monkey/Rabbit/Bovine CD51, Mr 125 & 24 kDa

Characteristics: Mouse Anti-Human CD51-UNLB

Purification: Purified

Immunogen: Cell suspension containing osteoclasts from osteoclastomas

Isotype: IgG1

Application Details

Application Notes: Working Dilution:
FACS: 1 µg/10^6 cells
Representative data are included in this product insert.

Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.

Sample Volume: 1 mL

Restrictions: For Research Use only

Handling

Buffer: Product is supplied as 0.1 mg purified immunoglobulin in 1.0 mL of phosphate buffered saline containing 0.1 % PBS / NaN3 and a stabilizing agent.

Handling Advice: Each reagent is stable for the period shown on the bottle label if stored as directed.

Storage: 4 °C

Target Details for CD51

Target: CD51 (ITGAV) (Integrin alpha V (ITGAV))

Alternative Name: CD51

Background: CD51 represents the 150 kDa integrin V chain that associates with integrin 3 (CD61) to form the CD51/CD61 vitronectin receptor on endothelial cells, certain activated leukocytes, NK cells, macrophages, neutrophils and platelets. CD51 is the most promiscuous integrin a subunit, it can form heterodimers with the 1 (CD29), 3 (CD61), 5, 6 and 8 subunits in various tissues. CD51/CD61 acts as an activation-independent receptor for platelet attachment and spreading on vitronectin and other RGD-containing proteins, including matrix components. It also mediates leukocyte-endothelial cell adhesion via interaction with CD31.

Pathways: Cell-Cell Junction Organization, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Integrin Complex